- Home
- CRT vs IMMP Comparison
CRT vs IMMP Comparison
Compare CRT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | IMMP |
|---|---|---|
| Founded | 1991 | 1987 |
| Country | United States | Australia |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 61.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | CRT | IMMP |
|---|---|---|
| Price | $9.96 | $0.39 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 14.9K | ★ 204.2K |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $0.29 |
| 52 Week High | $11.10 | $3.53 |
Technical Indicators
Market Signals| Indicator | CRT | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 48.78 |
| Support Level | $9.29 | $0.35 |
| Resistance Level | $10.25 | $0.46 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 43.46 | 61.24 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.